Acres Bruce, Limacher Jean-Marc, Bonnefoy Jeanoy
Transgene SA, Department of Medical Affairs, 11 rue de Molsheim, 67082 Strasbourg, France.
Curr Opin Drug Discov Devel. 2007 Mar;10(2):185-92.
Over the past century, various efforts have been made to induce the rejection of cancerous tissues by the stimulation of an immune reaction, using both non-specific and antigen-specific strategies. Non-specific approaches attempt to augment an immune response in and around the tumor by injecting immune stimulating substances, for example, bacterial extracts, cytokines or gene therapy agents. Antigen-specific approaches use either the tumor cells themselves as a source of antigens or incorporate identified tumor-associated antigens into vaccines. This review describes antigen-specific therapeutic cancer vaccines that are currently in development.
在过去的一个世纪里，人们通过使用非特异性和抗原特异性策略，刺激免疫反应来诱导癌组织的排斥，做出了各种努力。非特异性方法试图通过注射免疫刺激物质，例如细菌提取物、细胞因子或基因治疗剂，来增强肿瘤内部和周围的免疫反应。抗原特异性方法要么使用肿瘤细胞本身作为抗原来源，要么将已鉴定的肿瘤相关抗原纳入疫苗。这篇综述描述了目前正在研发的抗原特异性治疗性癌症疫苗。
